St. Louis, MO
Home ► Blog ► FDA & Prescription Drugs ► Diabetes Drugs
(December 11, 2017) — The 9th Circuit U.S. Court of Appeals decided on Wednesday to reverse the dismissal of all incretin cases involved in incretin lawsuit MDL 2452, which had been previously dismissed by the Southern District of California tr Read More »
The SGLT2 inhibitor Invokana has come under fire recently because of the increased risk of lower limb amputations caused by one of its key ingredients, canagliflozin. Physicians in California are hurrying to switch patients from Invokana to other dia Read More »
On November 25, United States District Court Judge Anthony J. Battaglia issued an order calling for “Science Day” hearings, a special type of hearing typical in complex pharmaceutical drug litigation proceedings. These hearings, which wil Read More »
In August 2013, the increasing number of lawsuits against drug manufacturers, Merck and Amylin led to the creation of a multidistrict litigation in the Southern District of California. Plaintiffs claim that diabetic drugs, Januvia and Byetta, cause s Read More »
Scientific journals, studies and advocacy groups join the FDA in questioning the safety of the Type 2 diabetes drug class referred to as incretin mimetics, which includes brand name drugs such as Byetta, Bydureon, Victoza, Januvia and Janumet.
Read More »
As lawsuits move forward, individuals diagnosed with pancreatitis or pancreatic cancer after taking type 2 diabetes medications are advised to determine their legal rights – Read More »
Tor Hoerman and Jake Plattenberger named to leadership roles in diabetes drugs pancreatic cancer lawsuit consolidated in front Judge Anthony J. Battaglia in the Southern District of California.
Read More »
Litigation over diabetes drugs that manage blood insulin levels, referred to as Incretin Mimetics, continues to move forward. Plaintiffs and their families throughout the Country have alleged that they now suffer or have died from pancreatic cancer a Read More »
On July 10, 2013, a federal district court judge in San Diego rejected Amylin Pharmaceutical’s bid to avoid having to defend Byetta-induced pancreatic cancer cases in California state court.
Read More »
Contact us by phone at 1-888-508-6752 or email us below.
© 2017 TorHoerman Law LLC.
The contents of this webpage have been prepared by TorHoerman Law, LLC for informational purposes only. None of this information is intended as either legal or medical advice or opinions. No attorney/client relationship is established with use of this website. Sending or receiving information through this site, posting to our blogs/news site does not establish an attorney/client relationship. An attorney/client relationship with TorHoerman Law is established only by an express and written agreement by TorHoerman Law to represent you. Our attorneys make a case-by-case assessment of any claims and results may vary depending on the facts concerning any case. The attorneys at TorHoerman Law are licensed to practice in Illinois, Missouri, and California. In some circumstances, cases may be sent to other qualified lawyers. In those circumstances, TorHoerman Law maintains joint responsibility.
Wesite Design & Development by Kaizen Coding